Cinromide

Cinromide is an anticonvulsant agent. Cinromide inhibits epithelial neutral amino acid transporter B0AT1 (SLC6A19) with an IC50 of 0.5 μM[1][2].

Product Specifications

CAS Number

[58473-74-8]

Product Name Alternative

Trans-3-Bromo-N-ethylcinnamamide

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Amino acid Transporter

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Cinromide.html

Purity

99.83

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(NCC)/C=C/C1=CC=CC(Br)=C1

Molecular Formula

C11H12BrNO

Molecular Weight

254.12

Precautions

H302, H315, H319, H335

References & Citations

[1]Chiu P, et al. The effect of cinromide on "kindled" seizures in the rat. Neuropharmacology. 1982;21 (3) :273-276.|[2]Yadav A, et al. Novel Chemical Scaffolds to Inhibit the Neutral Amino Acid Transporter B0AT1 (SLC6A19), a Potential Target to Treat Metabolic Diseases. Front Pharmacol. 2020;11:140. Published 2020 Feb 28.|[3]Soroko FE, et al. Cinromide (3-bromo-N-ethylcinnanamide), novel anticonvulsant agent. J Pharm Pharmacol. 1981 Nov;33 (11) :741-3.|[4]Fromm GH, et al. Effect of cinromide on inhibitory and excitatory mechanisms. Epilepsia. 1983 Aug;24 (4) :394-400.